Evogene (EVGN) Misses Q3 EPS by 1c

Evogene (NASDAQ: EVGN) reported Q3 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $311 thousand versus the consensus estimate of $270 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Syra Health names Dr. Cori McMahon as fractional chief medical officer
• Unum Group (UNM) PT Raised to $94 at UBS on Second LTC Deal